Contineum Therapeutics, Inc.
CTNM
$11.43
-$0.10-0.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.62% | -18.48% | 20.25% | -0.31% | -9.78% |
| Total Depreciation and Amortization | -2.35% | 4.94% | 2.53% | 1.28% | 4.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.88% | -1.64% | 25.60% | -13.48% | 92.97% |
| Change in Net Operating Assets | -713.54% | 68.11% | -18.51% | -78.74% | -136.68% |
| Cash from Operations | -24.72% | -6.93% | 22.12% | -8.67% | -41.27% |
| Capital Expenditure | -642.86% | 57.14% | -122.73% | 6.38% | 71.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.75% | -415.25% | 7.98% | -6.91% | 262.24% |
| Cash from Investing | 17.16% | -417.60% | 7.61% | -6.91% | 258.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.79% | 387.18% | 7,085.39% | 1,012.50% | -96.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 54.55% | -- | -- |
| Cash from Financing | -99.86% | 389.22% | 20,894.51% | 279.17% | -96.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -268.17% | 50.90% | 1,395.91% | -419.92% | 102.78% |